{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:14:08Z","timestamp":1793675648597,"version":"4.5.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019486","name":"Biocodex Microbiota Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019486","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030905","name":"Suomen Parkinson-s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030905","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ejps.2025.107133","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T11:49:17Z","timestamp":1747741757000},"page":"107133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Targeting bacterial and human levodopa decarboxylases for improved drug treatment of Parkinson's disease: Discovery and characterization of new inhibitors"],"prefix":"10.1016","volume":"211","author":[{"given":"Saku","family":"Reunanen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Ghemtio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayendra Z.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshit R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerttu","family":"Airavaara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jari","family":"Yli-Kauhaluoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jeltsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Xhaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petteri T.","family":"Piepponen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4697-8066","authenticated-orcid":false,"given":"P\u00e4ivi","family":"Tammela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2025.107133_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-024-06330-2","article-title":"Mitigating gut microbial degradation of levodopa and enhancing brain dopamine: implications in Parkinson\u2019s disease","volume":"7","author":"Cheng","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejps.2025.107133_bib0002","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/tcr.10005","article-title":"From cofactor to enzymes. The molecular evolution of pyridoxal-5\u2032-phosphate-dependent enzymes","volume":"1","author":"Christen","year":"2001","journal-title":"Chem. Rec."},{"key":"10.1016\/j.ejps.2025.107133_bib0003","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00003088-200241040-00003","article-title":"Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson\u2019s disease","volume":"41","author":"Deleu","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2025.107133_bib0004","first-page":"590","article-title":"Medical management of Parkinson\u2019s disease","volume":"33","author":"Goldenberg","year":"2008","journal-title":"Pharm. Ther."},{"issue":"s1","key":"10.1016\/j.ejps.2025.107133_bib0005","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3233\/JPD-179004","article-title":"L-Dopa","volume":"7","author":"Hornykiewicz","year":"2017","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.ejps.2025.107133_bib0006","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14383","article-title":"Piperine improves levodopa availability in the 6-OHDA-lesioned rat model of Parkinson\u2019s disease by suppressing gut bacterial tyrosine decarboxylase","volume":"30","author":"Hu","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.ejps.2025.107133_bib0007","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2025.107133_bib0008","first-page":"eaau6323","article-title":"Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism","volume":"364","author":"Maini Rekdal","year":"2019","journal-title":"Science (1979)"},{"key":"10.1016\/j.ejps.2025.107133_bib0009","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1002\/adsc.201100386","article-title":"A high-throughput screening assay for amino acid decarboxylase activity","volume":"353","author":"M\u00e9dici","year":"2011","journal-title":"Adv. Synth. Catal."},{"key":"10.1016\/j.ejps.2025.107133_bib0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archneur.1971.00490010049007","article-title":"Metabolism of Levodopa in patients with Parkinson\u2019s Disease: radioactive and fluorometric assays","volume":"25","author":"Morgan","year":"1971","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ejps.2025.107133_bib0011","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00002826-198403000-00002","article-title":"Pharmacokinetics of Levodopa","volume":"7","author":"Nutl","year":"1984","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ejps.2025.107133_bib0012","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1128\/AEM.01958-08","article-title":"Dual role for the tyrosine decarboxylation pathway in Enterococcus faecium E17: response to an acid challenge and generation of a Proton motive force","volume":"75","author":"Pereira","year":"2009","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.ejps.2025.107133_bib0013","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/mds.21537","article-title":"Prognostic factors for the progression of Parkinson\u2019s disease: a systematic review","volume":"22","author":"Post","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejps.2025.107133_bib0014","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/j.1432-1033.1994.tb18816.x","article-title":"Multiple evolutionary origin of pyridoxal-5\u2019-phosphate-dependent amino acid decarboxylases","volume":"221","author":"Sandmeier","year":"1994","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejps.2025.107133_bib0015","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrmicro.2016.17","article-title":"The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism","volume":"14","author":"Spanogiannopoulos","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejps.2025.107133_bib0016","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41467-019-08294-y","article-title":"Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson\u2019s disease","volume":"10","author":"van Kessel","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejps.2025.107133_bib0017","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1021\/cn5001759","article-title":"Classics in chemical neuroscience: levodopa","volume":"5","author":"Whitfield","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejps.2025.107133_bib0018","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1096\/fj.10-174383","article-title":"A novel approach to inhibit intracellular vitamin B6-dependent enzymes: proof of principle with human and plasmodium ornithine decarboxylase and human histidine decarboxylase","volume":"25","author":"Wu","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.ejps.2025.107133_bib0019","article-title":"Association between microbial tyrosine decarboxylase gene and levodopa responsiveness in patients with Parkinson Disease","author":"Zhang","year":"2022","journal-title":"Neurology"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725001320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725001320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:24:06Z","timestamp":1762331046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098725001320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":19,"alternative-id":["S0928098725001320"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107133","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting bacterial and human levodopa decarboxylases for improved drug treatment of Parkinson's disease: Discovery and characterization of new inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107133","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107133"}}